Lectil

Betahistine Dihydrochloride, the active ingredient in Lectil, is a histamine H1 receptor agonist / H3 antagonist presented as an oral formulation for systemic use. It is employed to alleviate vestibular symptoms such as vertigo and tinnitus, particularly in conditions like Ménière's disease, in adult patients.

GNH USA supplies Lectil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lectil acts on the vestibular system to reduce episodes of dizziness and related auditory disturbances. - Ménière's disease: helps decrease the frequency and intensity of vertigo attacks and associated tinnitus. - Vertigo: reduces the sensation of spinning and improves balance in patients with vestibular dysfunction.

Betahistine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Gastric discomfort: mild abdominal pain. - Skin rash: transient erythema. - Dizziness: rarely persists after treatment.

Serious or Rare Side Effects: - Allergic reaction: urticaria, angioedema, or anaphylaxis. - Severe hypotension: marked blood pressure drop. - Cardiac arrhythmia: uncommon but reported in susceptible individuals. - Hepatic dysfunction: elevated liver enzymes in rare cases. - Hematologic abnormalities: thrombocytopenia or leukopenia.

Before initiating therapy, consider the following safety measures. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: unknown excretion; evaluate risk versus benefit. - Renal impairment: monitor renal function and adjust if necessary. - Concomitant antihistamines: may blunt therapeutic effect. - Elderly patients: start at lower dose and monitor tolerance. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and direct sunlight.

Betahistine may interact with other agents affecting histamine pathways or cardiovascular function.

Major Interactions (Avoid): - Strong antihistamines (e.g., diphenhydramine): may negate betahistine’s action. - Monoamine oxidase inhibitors: risk of hypertensive episodes.

Moderate Interactions (Monitor Closely): - Vasodilators (e.g., nitrates): additive blood pressure lowering. - Anticholinergic drugs: possible increase in dizziness. - Diuretics: monitor electrolyte balance. - CYP450 substrates: potential alteration of metabolism, though clinical relevance is limited.